SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

DLBCL Clinical Trial

Official title:

Selinexor Combined With Prednisone, Etoposide, and Lenalidomide as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for Refractory Diffuse Large B-cell Lymphoma With p53 and/or c-Myc Expression

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05498636
• Other study ID #: 202201
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: August 2022
• Source: The Affiliated Hospital of Qingdao University
• Contact: Hongwei Xue, doctor
• Phone: +8613475875599
• Email: hwx326[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 67
• Est. completion date: December 31, 2025
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Any of the following as defined by the WHO, 2016 lymphoid neoplasm classifications and histologically confirmed:Diffuse large B-cell lymphoma with p53 and/ or c-Myc protein overexpression. Note: a. The cutoff value for p53 protein overexpression by immunohistochemistry (IHC) is 50%; cutoff value for c-Myc protein overexpression is 30-40%; b. For patients with high expression of C-Myc, dual-color FISH probes detection method should be used to check whether there is Myc and BCL2 gene rearrangement, which is cut by 5%; c. We need 5-10 pathological white films with a thickness of 5-10 um for review.

2. Patients who cannot tolerate or are unwilling to undergo intensive salvage therapy due to age or frailty; patients who have received at most three prior lines of regimen, in which stem cell transplantation is considered first-line.

3. With a life expectancy of = 3 months

4. Age = 18 years

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

6. At least 1 evaluable or measurable lesion that meets Lugano2014 criteria [Evaluable lesions: PET/CT examination showed increased uptake in lymph nodes or extranodal areas (higher than that in the liver), and pet/ct features were consistent with lymphoma. Measurable disease: Nodular lesions with longest diameter (LDi) greater than > 15mm or extranodal lesion with LDi >10mm. and FDG-PET positive lesions]

7. All screening laboratory tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: Routine blood tests (no blood transfusion, no G-CSF, no drug correction within 14 days before screening) : a. Hb=80g/L;b.ANC=1.0×109/L;c.PLT=75×109/L. Blood biochemistry: a.TBIL=1.5×upper limit of normal (ULN), or TBIL=3×ULN(if due to liver involvement); b. ALT and AST=3×ULN, or AST and ALT=5.0 x ULN(if due to liver involvement); c. Serum creatinine =1.5×ULN, or Estimated creatinine clearance = 50 mL/min (calculated using the formula of Cockcroft-Gault). Coagulation function (unless the subject is receiving anticoagulant treatment and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant treatment at the time of screening): INR=1.5×ULN; APTT=1.5×ULN.

8. Written informed consent of the patient

Exclusion Criteria:

1. Patient with hemophagocytic syndrome

2. With uncontrolled serious active infections, including active tuberculosis

3. Known to have central nervous system (CNS), testicular, breast lymphoma; Patients with massive pleural and peritoneal effusion

4. Previous treatment with Selinexor or lenalidomide in the past 6 months

5. Previous treatment with allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation.

6. Autologous hematopoietic stem cell transplantation was performed within 6 months prior to initiation of treatment.

7. Major surgery <28 days of C1D1.

8. Live vaccine (excluding attenuated influenza vaccine) within 28 days before study treatment.

9. Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 4 weeks from the end of treatment in the previous clinical study.

10. Patients with serious medical diseases, such as organic heart disease, resulting in clinical symptoms or cardiac dysfunction (=NYHA grade 2), a history of myocardial infarction within 6 months prior to screening, echocardiographic ejection fraction < 50%, and severe thromboembolic diseases.

11. Positive HIV serologies before inclusion.

12. Other malignant tumors in the past 5 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and gastrointestinal intramucosal carcinoma after radical treatment.

13. Additional systemic antitumor therapy may be accepted during the study period.

14. Other conditions that patients considered unsuitable for inclusion by the researchers.

Related Conditions & MeSH terms

• DLBCL

Intervention

Combination Product:
• Selinexor combined with Prednisone, Etoposide, and Lenalidomide
Selinexor combined with Prednisone, Etoposide, and Lenalidomide

Locations

Country	Name	City	State
China	the affiliated hospital of Qingdao University	Qingdao	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of Qingdao University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CR rate	complete remission rate after 4 cycles of SPEL regimen	At the end of Cycle 4 (each cycle is 28 days)
Primary	ORR	overall response rate after 4 cycles of SPEL regimen	At the end of Cycle 4 (each cycle is 28 days)
Secondary	AE	adverse event of SPEL regimen	from the first dose of SPEL regimen to 3 months after last dose of the regimen